|
MechanismCRTH2 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismCRTH2 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismCRTH2 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
TM30339: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Repeated Subcutaneous Dose-range Study Designed to Determine the Weight Loss in Obese Subjects.
The purpose of this study is to determine the effects of TM30339 on weight loss in obese individuals after 28 days dosing.
A multi-centre, randomized, double-blind, placebo-controlled, parallel-group study in obese subjects investigating weight loss after repeated, subcutaneous doses of TM30338
100 Clinical Results associated with 7TM A/S
0 Patents (Medical) associated with 7TM A/S
100 Deals associated with 7TM A/S
100 Translational Medicine associated with 7TM A/S